- Home
- WALD vs EDIT Comparison
WALD vs EDIT Comparison
Compare WALD & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WALD
- EDIT
- Stock Information
- Founded
- WALD 1988
- EDIT 2013
- Country
- WALD United States
- EDIT United States
- Employees
- WALD N/A
- EDIT N/A
- Industry
- WALD Package Goods/Cosmetics
- EDIT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- WALD Consumer Discretionary
- EDIT Health Care
- Exchange
- WALD Nasdaq
- EDIT Nasdaq
- Market Cap
- WALD 238.6M
- EDIT 269.8M
- IPO Year
- WALD 2021
- EDIT 2016
- Fundamental
- Price
- WALD $1.99
- EDIT $3.95
- Analyst Decision
- WALD Strong Buy
- EDIT Buy
- Analyst Count
- WALD 5
- EDIT 11
- Target Price
- WALD $4.96
- EDIT $4.56
- AVG Volume (30 Days)
- WALD 133.9K
- EDIT 2.8M
- Earning Date
- WALD 11-11-2025
- EDIT 11-03-2025
- Dividend Yield
- WALD N/A
- EDIT N/A
- EPS Growth
- WALD N/A
- EDIT N/A
- EPS
- WALD N/A
- EDIT N/A
- Revenue
- WALD $273,868,000.00
- EDIT $38,901,000.00
- Revenue This Year
- WALD $10.37
- EDIT N/A
- Revenue Next Year
- WALD $14.37
- EDIT N/A
- P/E Ratio
- WALD N/A
- EDIT N/A
- Revenue Growth
- WALD 25.55
- EDIT N/A
- 52 Week Low
- WALD $1.48
- EDIT $0.91
- 52 Week High
- WALD $4.18
- EDIT $4.07
- Technical
- Relative Strength Index (RSI)
- WALD 56.70
- EDIT 71.08
- Support Level
- WALD $1.82
- EDIT $3.01
- Resistance Level
- WALD $1.97
- EDIT $4.06
- Average True Range (ATR)
- WALD 0.11
- EDIT 0.30
- MACD
- WALD -0.00
- EDIT 0.08
- Stochastic Oscillator
- WALD 57.38
- EDIT 89.89
About WALD Waldencast plc
Waldencast PLC is a beauty and wellness operating platform. The company is organized into two reportable segments namely Obagi Skincare and Milk Makeup. The company generates the majority of its revenue from the Obagi Medical segment. The Obagi Medical segment is engaged in developing, marketing, and selling skin health products. The Milk Makeup segment includes developing, marketing, and selling cosmetics, skincare, and other beauty products. Geographically the company generates the majority of its revenue from North America region.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.